A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD

  • End date
    Mar 31, 2027
  • participants needed
  • sponsor
    University of Regensburg
Updated on 29 May 2022
cell transplantation
hemoglobin s
acute chest syndrome
chest syndrome
sickle hemoglobin
exchange transfusion


HSCT is currently the only curative option for SCD but less than 20% of SCD patients have a MD donor available. So far, all curative approaches beyond a MSD HSCT at young age are non-satisfactory. With the lack of a suitable donor for the vast majority of patients, the major question of this trial is, if a haploidentical αß/CD19+ T-cell depleted HSCT can be a valid alternative to a MSD HSCT. The main challenge in non-malignant diseases is to offer a safe and GvHD-free HSCT without rejection.


Can an α/ß depleted T-Haplo-HSCT with regard to disease free survival, adverse events and safety be considered equivalent to a matched sibling donor transplantation (MSD), in order to offer cure for the majority of patients with sickle cell disease.

The main questions of this trial are:

  • Safety of a α/ß T-depleted haploidentical HSCT
  • Incidence of acute and chronic GvHD
  • Rate of rejection
  • Immune reconstitution
  • Fertility It is expected that the use of TCRαβ+ and CD19+ depleted haploidentical cell grafts in combination with the less aggressive and well tolerated conditioning regimen needed for patient preparation will be associated with a low risk of grade II-IV aGVHD and no extensive cGvHD, no graft failure and increase speed, spectrum and functionality of immune system reconstitution. This is supposed to reduce the incidence of severe infections leading to lower rates of transplantation related mortality (TRM).

Condition HbS Disease, Hemoglobin S Disease, Sickle Cell Anemia, Sickle Cell Disorders, Sickling Disorder Due to Hemoglobin S, Sickle Cell Disease
Treatment TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation, Matched sibling donor transplantation
Clinical Study IdentifierNCT04201210
SponsorUniversity of Regensburg
Last Modified on29 May 2022


Yes No Not Sure

Inclusion Criteria

Age 1yr to 35yrs
Homozygous hemoglobin S disease or heterozygous hemoglobin SC or S 0/+
Study specific consent given
Preexisting severe or moderate SCD related complications
Clinically significant neurological event (stroke) or deficit
Silent crisis, neurocognitive deficit
Pathological angio-MRI with TOF Sequence
TCD velocity >200 cm/s at 2 occasions >1 month apart
More than 5 vaso-occlusive crises (VOC) in the past 1 year or more than 20 VOC in a lifetime
Two or more episodes of acute chest syndrome (ACS) in a lifetime or one episode of ACS in the past 24 months
Chronic transfusion requirement or more than 8 transfusions or one exchange transfusion in a lifetime
Transfusion-refractory allo-immunization
More than five SCD-related hospitalizations in a lifetime
Beginning pulmonary hypertension
Osteonecrosis at more than 2 sites
Beginning SCD Nephropathy
Recurrent priapism (>2)

Exclusion Criteria

Karnofsky or Lansky Performance Score < 70%
Patients with donor-specific antibodies (DSA) against the potential stem cell donor by either
Cell-based crossmatched assays (Complement-dependent cytotoxicity; CDC) or
Flow cytometry crossmatch test or
Solid-phase immunoassays (SPI) or
Modified SPI such as C4d and C1q assays Whichever method the participating center is experienced in
Patients with major AB0 incompatibility defined according to EBMT Handbook, Edition
ABO incompatibility Recipient Donor Major O A O B O AB A AB B AB
Tab 23.1
Cardiac function
Ejection fraction at rest <45.0% on echocardiography or
Shortening fraction of <27.0% by echocardiogram or radionuclide scan (MUGA)
Patients with > grade II hypertension by Common Toxicity Criteria (CTC)
Renal function
Estimated creatinine clearance (for patients > 12 years) greater than 50.0 mL/minute
for pediatric patients (> 1 year to 12 years), GFR estimated by the updated Schwartz formula ≥ 90.0 mL/min/1.73 m2. If < 90 mL/min/1.73 m2, renal function must be measured by 24-hour creatinine clearance or nuclear GFR and must be > 70.0 mL/min/1.73 m2 or
Creatinine clearance below threshold defined for stem cell transplantation according to local clinical standard
Pulmonary function
DLCO >50% (adjusted for hemoglobin), and FVC and FEV1≥50%; children unable to perform for PFTs, O2 saturation <92% on room air
Liver function
Total bilirubin > 2x the upper limit of normal (unless elevated bilirubin is attributed to Gilbert's Syndrome) and ALT/AST > 2.5x the upper limit of normal
Chronic active viral hepatitis
Adults of reproductive potential not willing to use an effective method of birth control during study treatment and for at least 12 months thereafter
Women who are pregnant (positive serum or urine βHCG) or breastfeeding. Note: Women of
History of uncontrolled autoimmune disease or on active treatment
childbearing potential must have a negative serum pregnancy test at study
Patient unable to comply with the treatment protocol
Prior autologous or allogeneic hematopoietic stem cell transplant
Vaccination with a live virus vaccine during the trial
HIV infection
Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism/drug addiction)
Patients unwilling or unable to comply with the protocol or unable to give informed consent
Concurrent severe or uncontrolled medical disease (e.g. uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months prior to the study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which by assessment of the treating physician could compromise participation in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note